NanoHybrids enables personalized disease management by commercializing nanotechnology-based products that can enhance the detection and molecular profiling of cancer and other diseases non-invasively.
Our products are nano-sized agents that enhance contrast in biomedical imaging techniques by interacting specifically with diseased cells and allowing for real time imaging of functional biology. The contrast agents can be employed in a wide variety of optical and acoustic biomedical imaging approaches in preclinical and clinical applications.
NanoHybrids is leveraging patented nanotechnology developed within the academic research of its founders and management team from The University of Texas at Austin and M.D. Anderson Cancer Center.